[Theory for prophylactic AIDS vaccine development].
In the natural courses of human immunodeficiency virus (HIV) infections, host immune responses fail to contain the virus and allow persistent HIV replication, leading to AIDS progression. For development of an effective vaccine against those viral infections which do not show spontaneous remission, it is important to elucidate which immune responses to be induced for viral control. This review focuses on antibodies and cytotoxic T lymphocytes, key adaptive immune effectors, and discusses possible mechanisms for HIV control by vaccine-induced antibody, memory B lymphocyte, and (effector and central) memory T lymphocyte responses. Finally, we mention the ongoing international project for a clinical trial of our Sendai virus vector-based AIDS vaccine.
Nomura
Takushi
T
International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. nomutaku@ims.u-tokyo.ac.jp
Matano
Tetsuro
T
D016915:AIDS Vaccines / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D001402:B-Lymphocytes / Q000276:immunology; D002986:Clinical Trials as Topic; D006678:HIV / Q000502:physiology; D015483:HIV Antibodies / Q000276:immunology; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014779:Virus Replication
D016915:AIDS Vaccines; D015483:HIV Antibodies